203 related articles for article (PubMed ID: 24766469)
1. Emerging therapies for refractory chronic lymphocytic leukemia.
Kutsch N; Hallek M; Eichhorst B
Leuk Lymphoma; 2015 Feb; 56(2):285-92. PubMed ID: 24766469
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
3. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
5. Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):701-709. PubMed ID: 27055577
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy of CLL.
Al-Sawaf O; Fischer K; Eichhorst B; Hallek M
Oncol Res Treat; 2016; 39(12):768-778. PubMed ID: 27889784
[TBL] [Abstract][Full Text] [Related]
8. Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.
Kittai AS; Woyach JA
Cancer J; 2019; 25(6):428-435. PubMed ID: 31764124
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia.
Byrd JC; Stilgenbauer S; Flinn IW
Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
Byrd JC; Lin TS; Grever MR
Semin Oncol; 2006 Apr; 33(2):210-9. PubMed ID: 16616068
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
D'Souza P; Walker G
Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
[TBL] [Abstract][Full Text] [Related]
14. The treatment of relapsed refractory chronic lymphocytic leukemia.
Brown JR
Hematology Am Soc Hematol Educ Program; 2011; 2011():110-8. PubMed ID: 22160021
[TBL] [Abstract][Full Text] [Related]
15. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
Rainone M; Siddiqi T
Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
[TBL] [Abstract][Full Text] [Related]
17. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
18. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
[TBL] [Abstract][Full Text] [Related]
19. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
[TBL] [Abstract][Full Text] [Related]
20. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Lin TS
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
